D4T available on `parallel track.'

December 1992
FDA Consumer;Dec92, Vol. 26 Issue 10, p7
Reports that the investigational drug D4T is the first drug to be available under the Food and Drug Administration's `parallel track' policy. The drug to treat people with AIDS was made available for expanded investigational use last Oct. 5. How D4T acts by inhibiting the AIDS virus; More.


Related Articles

  • Up-to-date. Horton, Kathleen // Pharmaceutical Executive;Sep97, Vol. 17 Issue 9, p158 

    Focuses on the `AIDS Reference Manual,' which provides a comprehensive information for those involved in all aspects of AIDS and its treatment. Topics included in the manual; Price of the manual; Contact information.

  • THE SHRINKING OF AIDS. Andriote, John-Manuel // Advocate;10/27/87, Issue 484, p47 

    Discusses psychological issues involved in the treatment of AIDS, according to the American Psychological Association (APA). Patients' coping with the incurable disease; Position of APA concerning the disease; Psychological ramifications of the manifestation of AIDS.

  • Zalcitabine offers new option for AIDS patients. Rodgers, Katie // Drug Topics;9/5/94, Vol. 138 Issue 17, p16 

    Reports on the Food and Drug Administration (FDA) approval of the zalcitabine drug as a treatment option for AIDS patients. Comparative study with didanosine; Common adverse events observed; Hivid monotherapy from Hoffman-La Roche.

  • Progress reports in the battle against acquired immune deficiency syndrome.  // FDA Consumer;Apr89, Vol. 23 Issue 3, p4 

    Provides an update on progress being made in fight against acquired immune deficiency syndrome (AIDS). U.S. Food and Drug Administration (FDA) approved wider use of aerosolized pentamidine to prevent pneumonia in AIDS patients; Studies expended for drug foscarnet used to treat cytomegalovirus...

  • Information package for cytokine therapy.  // FDA Consumer;Mar1991, Vol. 25 Issue 2, p7 

    Announces that an information package developed by the Food and Drug Administration is available for potential sponsors of cytokine and growth factor therapies for AIDS. Details on cytokines and what is contained in the package.

  • DDC available under treatment IND.  // FDA Consumer;Sep91, Vol. 25 Issue 7, p9 

    Reports that an experimental AIDS drug is now available to patients with AIDS or advanced AIDS-related complex who cannot tolerate or have not benefited from the only approved AIDS treatment, zidovudine (commonly called AZT).

  • Emergency funds for 16 cities.  // FDA Consumer;Sep91, Vol. 25 Issue 7, p9 

    Announces that emergency funds totaling $43 million will go to 16 United States cities hit particularly hard by the AIDS epidemic. The funds will support health and social services for people with AIDS and HIV disease. Details on recipients.

  • DDI: Wider access, lower doses.  // FDA Consumer;Dec92, Vol. 26 Issue 10, p7 

    Reports that wider access to and lower doses of the anti-HIV drug Videx (didanosine, or DDI) have been approved for any patient who has been treated with AZT (zidovudine), according to a Food and Drug Administration announcement on Oct. 1. Videx's initial approval in 1991; How patients given...

  • Whether no means no. Silverman, Lewis M.; Rouse, Fenella // Hastings Center Report;May/Jun92, Vol. 22 Issue 3, p26 

    Presents a hypothetical case study about an HIV positive emergency room patient, Mr. R, complaining of shortness of breath. Mr. R's proxy, Mr. U; Mr. R enters anaphylactic shock; Dr. D's belief in patient autonomy; Commentary by four experts; Lesson learned by the case; More.


Read the Article

Other Topics